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Introduction
Platelet-rich plasma (PRP) is a volume of plasma of
autologous blood having platelet levels above peripheral
blood concentration.1 The concentration of platelets may
provide a higher amount of several bioactive growth fac-
tors reported to promote healing, but the methods used
vary considerably, affecting the overall quality of the
platelets, outcome, and costs.2,3 Humans have an average
baseline blood platelet count of 200,000 ± 75,000/µL and
platelets have an in vivo half-life of ~7-10 days. Activat-
ed platelets, upon contact with exposed endothelium with-
in wounds or damaged tissues, are known to release key
wound healing factors including platelet-derived growth
factor (PDGF), transforming growth factor (TGF), vascu-
lar endothelial growth factor (VEGF), insulin-like growth
factor (IGF), and epidermal growth factor (EGF).4,5 All of
these factors set the stage for tissue healing (Fig. 1) which
involves intricate overlapping processes that are often cat-
egorized into haemostasis, inflammation, proliferation, and
remodelling (Fig. 2). Once tissue injury occurs, a
haematoma forms at the site of tissue damage, platelets
adhere to exposed collagen creating a clot, and the in-
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Fig. 1 - Growth factors secreted by platelets including platelet-derived
growth factor, fibroblast growth factor, transforming growth factor be-
ta, epithelial growth factor, and vascular endothelial growth factor.
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flammatory phase begins with activation of platelets re-
sulting in release of growth, bioactive, and haemostatic
factors.5 Each factor plays a unique but important inte-
grating role in the early stages of the intrinsic and extrin-
sic pathways of the clotting cascade. Access to the wound
site by neutrophils and macrophages occurs within hours
of injury thereby initiating the phagocytosis of tissue de-
bris. Within a few days of injury, the proliferative phase
begins and this is characterized by angiogenesis, collagen
deposition, granulation tissue formation, epithelialization,
and wound contraction. Finally, the remodelling phase in-
volves collagen maturation and apoptosis of excess cells
which can take from several weeks to months after an in-
jury depending of the degree of damage. Based on the
above described model, acceleration of wound healing by
addition of PRP is based on various platelet growth fac-
tors (PGFs) that stimulate different stages of the wound
cascade. Compared to application of single, recombinant
growth factors, which are applied in supraphysiological
concentrations, PRP has the advantage of offering multi-
ple, synergistically working growth factors at the wound
site and in concentrations that are biologically and physi-
ologically more pertinent.
Although PRP seems to be used more frequently and
in routine medical practice, there are few robust and con-
trolled clinical trials which would establish precise clinical
protocols.6-8 Parameters that need to be included for com-
parative optimization of PRP preparation protocols include:
the absolute number and concentration of platelets over
baseline, the choice between exogenous pre-activation of
platelets or not, the number of injections or applications
(topical), and the delay between injections or applications.
It is the intention of this report to show that a simple pro-
tocol and common laboratory materials can be adapted to
standardize the preparation of PRP with the emphasis on
overall preservation of platelets’ physiological properties.
The protocol described can be reproduced in any clinical
setting, permitting a cost-effective delivery of growth fac-
tors, which may be instrumental in burn management.
Materials and methods
Kit preparation
Kits were prepared by the hospital pharmacy for the
blood harvest. These sterile kits contain 4.5 mL Vacutainer
tubes with sodium citrate solution and a final concentra-
tion of 3.8% sodium citrate (0.129 M). Alternatively, a
butterfly valve fitted to a 20 ml syringe with Cambi caps
for closure of the syringe end following blood harvesting
along with a 19 mm adapter can be used. When the sy-
ringe and butterfly are used for blood collection, a 20 g
needle is first attached to the syringe for collection of sodi-
um citrate solution (pharmacy preparation) and then trans-
ferred to the butterfly valve for patient use. These materi-
als are sealed inside a pouch (235 x 340 mm) (Fig. 3).
Minimal additional disposable laboratory tubes (50 ml cen-
trifuge tubes) and pipettes are necessary for processing. 
Fig. 2 - Overlapping stages following tissue damage until wound
healing. Phases and mechanisms of action throughout haemostasis,
inflammation, proliferation, and remodelling are illustrated. 
Fig. 3 - Prepared PRP kit containing 4.5 mL Vacutainer tubes (0.5
ml 3.2% sodium citrate), Vacutainer unit for blood harvesting with
19 mm adapter sealed inside pouch (235 x 340 mm). Blood pro-
cessing materials include syringes, needles, centrifuge tubes, pipettes,
and surgical gloves.
Blood harvest and centripetal PRP preparation method
Harvesting of whole blood from the patient vein di-
rectly can be accomplished into four 4.5 mL citrate (3.8%
sodium citrate)-containing Vacutainer tubes (clinical grade
borosilicate glass of non-pyrogenic, non-cytotoxic and nu-
clease free) or, alternatively, a syringe can be used to take
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3.8% citrate solution sterilely from a pharmaceutical prepa-
ration, and then attached to the butterfly valve just before
drawing blood from the patient.
In Lausanne, this is done in the out-patient clinic sit-
uated next to the hospital preparation laboratory for rapid
transfer and preparation. Under a laminar flow hood, the
blood from the tubes or syringe is transferred gently to a
50 ml centrifuge tube.
Centrifugation is accomplished with a Megafuge cen-
trifuge at 280 g for 15 min at room temperature. After the
first centrifugation, the PRP is carefully removed with a
pipette inserted above the buffy coat and transferred to a
new, sterile centrifuge tube. A second centrifugation
process is then made under the same conditions. Follow-
ing the second centrifugation, the concentrated PRP is tak-
en with a sterile syringe for clinical application. The vol-
ume obtained depends on the required concentration yield-
ing of 2-4 ml and is dependent on the clinical application.
In general, 1 ml is used for approximately 100-150 cm2
for burns and 10 cm2 for chronic wounds. The step-by-
step protocol is described in Table I. 
Certified laboratory technicians, cellular biologists, or
other health care professionals who have had PRP train-
ing and are familiar with proper aseptic technique can safe-
ly carry out the PRP preparation following the protocol in
Table I. After the blood withdrawal, the PRP can be pre-
pared in a laboratory, operating room or out-patient clin-
ic requiring only a table-top centrifuge for preparation, al-
though a laminar flow hood can increase security (Fig. 4).
Any physician using PRP techniques in therapy needs to
be familiar with specific guidelines in the use of blood
products and also have a clear understanding of possible
complications. The International Cellular Medical Society
stresses the need to establish standards for PRP prepara-
tion protocols, techniques, and traceability.9
Results
When anti-coagulated blood is centrifuged, three lay-
ers appear. This is due to differences in the density of the
blood components: the deep layer consists of red blood
cells, the middle layer contains platelets and leukocytes,
and the top layer is made up of platelet-poor plasma. The
bottom part of the middle layer is also called buffy coat
(bottom of circled region), which is rich in leukocytes. The
heterogeneity of blood samples from patients is variable
in the overall physical properties such as seen in the sam-
ples illustrated (Fig. 5) with clear to opaque plasma ob-
tained following several centrifugation protocols. The main
variables considered when optimizing the technique and
which play significant roles in PRP preparation included
the collecting agent, the choice whether or not to use an
activating agent (such as thrombin), and the concentration
protocols. These have to be adapted bearing in mind both
the quality and stability of the cellular elements and the
• Harvest patient blood with the aid of a syringe or Vacutainer
tubes (citrate tube. l0mM 3.8% final pharmaceutical grade)
• Identify the blood sample with patient speciﬁc labels and attach
two labels for the returning final preparation
• Place the syringe or the tubes in a sterile transfer box and
proceed to tissue/cell preparation room
• Spray the transfer box with 70% alcohol and transfer under
the laminar flow hood
• Open the box under the laminar flow hood
• Transfer the citrate-treated blood to a 50 ml Falcon centrifuge
tube (non-pyrogenic and sterile)
• Centrifuge the tube for 15 min at 280 g at room temperature
• After centrifugation, remove tube and spray with 70% alcohol
and transfer under the laminar flow hood.
• Remove platelets with a sterile 5 ml pipete and transfer plasma
and platelets to a new 50 ml Falcon centrifuge tube
• Centrifuge the tube for 15 min at 280 g at room temperature
• Keep the pellet with 1-2 ml plasma and transfer to a 2 ml
syringe (4-5 ml, 2 syringes for higher quantities)
• Close the syringe(s) with a sterile cap and attach a patient
label
• Still working under the laminar ﬂow hood, transfer the ﬁnal
preparation in 1-2 syringes to a new transfer box and place
a patient label on the outside before returning to patient
• Platelets are ready for use either for injection or topical 
application
Table I - Step-by-step PRP preparation
Blood processing materials
Sterile material Suggested manufactured
VacuTube Vacutainer, 4.5 mL sodium
citrate Becton Dickinson
Butterfly 19G Ospedalia, Becton
Dickinson
Syringes 20ml Luer Lock, 3 ml
Luer Lock, Combi cap for syringe B.Braun Medical SA
Needles 20G 55mm; 20G 40 mm Becton Dickinson
Tubes 50 ml Falcon
Sterile pipettes 5 & 10ml Falcon
Sterile surgical gloves
Fig. 4 - Description of procedure for two-step centrifugation prepa-
ration and heterogeneity of PRP preparations from two different
patients. Blood separation and manipulation under a laminar flow
hood. Following first centrifugation (280 g at 15 min) in a cen-
trifugation tube (50 ml), the three phases can be readily attained
with a visible buffy coat (circled) which includes the platelet phase.
This phase is isolated (5 ml sterile pipette), placed in a second ster-
ile centrifugation tube, and centrifuged (280 g for 15 min) to ob-
tain a platelet concentrate. Platelet pellet is suspended in a mini-
mum quantity of plasma (2-4 ml).
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importance of choosing an anticoagulant capable of pre-
serving the platelets’ best possible functionality, integrity,
and morphology. When no anticoagulant is used, platelets
can be activated by the mechanical stress of centrifuga-
tion. Citrate is a suitable anticoagulant for PRP prepara-
tion if the appropriate (i.e. sterile, non-pyrogenic) tubes
are available. It has been recently shown that thrombin-
activated PRP releases all growth factors at the same time
in a bolus, while non-activated PRP uses the platelets as
a sustained drug delivery system,10 exhibiting the best
wound healing effects. The centrifugation steps should be
as delicate as possible but allowing a clean separation of
the blood components. Performing two successive low
force centrifugations can contribute to platelet preserva-
tion. 
Variability can be seen in the total platelet count from
one patient to another and the overall goal was to achieve
a concentrating factor of 2-3 times in whole blood for any
given patient as indicated by the results from three repre-
sentative patients (Table II). The centrifugation steps ac-
complished at low centrifugation forces (280 g) limit me-
chanical stress to the cellular elements and are capable of
producing the concentration factor desired for clinical use.
These centrifugation forces are routinely used in our hos-
Fig. 5 - PRP preparations and heterogeneity between patients.
Platelets whole PRP after Concentration
blood processing factor
Patient 1 341,000/µl 874,000/µl 2.56
Patient 2 190,000/µl 446,500/µl 2.35
Patient 3 250,000/µl 707,500/µl 2.83
Table II - Results for platelet concentration following centrifugation
 Method Method description Kit price ($US) Time of preparation (min) Approximate
concentration factor
CHUV Table-top centrifuge 3.62 30 2-3
2x15 min 284g 
Cell saver based system COM.TEC de chez 175 20 4-5
www.fresenius-kabi.com Fresenius
Biomet System GPS II Druker 755 VES 700 30 8
www.biomet.com Centrifuge (1.5-3, literature)
RegenLab Standard 320 30 2-6
www.regenkit.com Centrifuge ß(1.3-2, literature)
Cytomedix Angel Computer aided 495 25 4-5
www.cytomedix.com system (variable depending
on blood volume)
Autologel System Cytomedix 325 1-2 2-4
www.cytomedix.com Centrifuge
Genesis CS Direct siphoning 1550 16 10
www.vet-stem.com Drucker 755 VES Centrifuge
Harvest Smart Prep2 BMAC Harvest Prep 420 16 6-8
www.harvesttech.com Centrifuge
Table III - Comparison between PRP centrifugation methods
Annals of Burns and Fire Disasters - vol. XXV - n. 4 - December 2012
211
pital laboratory for preparation of multiple cellular thera-
pies including autologous skin cell separation, culture and
grafting and allogenic skin cell separation and have there-
fore been optimized for clinically used cell therapies with
particular emphasis on overall cell quality.
The method of PRP preparation described uses com-
ponents available in most clinics, hospitals, and pharma-
cies and the overall cost is relatively low, taking all the
required elements together. This should be fairly compa-
rable and therefore affordable in any clinical setting world-
wide. We have compared the cost of our current hospital-
prepared kit with various other PRP kits available com-
mercially (Table III). Many of the kits are used with spe-
cialized equipment and centrifuges which augment the over-
all cost of PRP use, unlike most disposables associated
with our preparation which can be adapted to standard cen-
trifuge systems that are readily available in most clinic and
hospital settings. Small table-top centrifuges are capable of
the lower centrifugation forces that assure overall cell qual-
ity. The preparation times are directly associated with the
speed of centrifugation, and kits report from several min
up to as many as 30 min of centrifugation time required
with one or two-step processing. One important variable
reported is the approximate overall concentration factor
with some kits describing fairly high concentration possi-
bilities, but data from the literature sometimes indicate oth-
erwise.11 There are many ready-to-use commercially avail-
able disposable kits in the price range from $US 175-1150
per kit (price quotations given to our hospital), well above
the cost of the necessary materials we describe to produce
reliable PRP preparations (less than 4 USD). 
Discussion
PRP is an easily accessible cell therapy that helps treat
chronic wounds and severe burns. PRP is an autologous
cell therapy containing many bioactive factors that are in-
volved in wound healing and tissue repair, requiring only
minimal manipulation to obtain the final product. Howev-
er, understanding the differences in PRP preparations is
essential when interpreting clinical study results. There-
fore, since little standardization has been done to date,
there is still controversy as to the clinical benefits of PRP.
Large prospective and randomized studies are necessary to
investigate the efficacy of standardized preparations of PRP
and post-injection rehabilitation protocols.
When cell therapies are involved in the clinic, it is of
utmost importance to assure the quality of the cellular com-
ponent. In addition, high costs and the need to have spe-
cialized equipment to prepare PRP have critically reduced
the use of autologous platelets. In our opinion, more sim-
plified PRP preparation methods which do not require ad
hoc and costly equipment would help in accumulating clin-
ical data and in introducing the method more routinely in
clinical practice as also in the operating room. An impor-
tant variable that can have a critical impact on PRP qual-
ity is the centrifugation protocols, which until now have
been highly variable with respect to the force, time and
number of centrifugations.3,12 High centrifugation forces can
lead to activation of platelets during the preparation and
thus impair or diminish platelet function and activity on
the wound directly.6 In addition, using higher centrifuga-
tion forces than normal in order to have higher concen-
trations of PRP do not necessarily mean a more effective
therapy. On the contrary, Graziani et al. demonstrated in
an in vitro study that the biological stimulation of cell
growth varies with the dose. Comparison of different con-
centrations showed that moderate concentration rates of
2.5 fold gave better in vitro results on fibroblast and os-
teoblast proliferation and function than concentrations of
PRP that were less or more concentrated.13
Rappl et al.13 noted that studies with one to three times
concentrated PRP showed better results in wound healing
than those with higher concentrations. Studies within a
meta-analysis by Martinez-Martines-Zapata et al.14 revealed
that the works with beneficial PRP treatment did indeed
use protocols with lower platelet concentrations.
According to the Cochrane Report,8 there is currently
no evidence to suggest that autologous PRP is of value for
treating chronic wounds. The reports analysed were based
on small numbers of randomized controlled studies for the
treatment of chronic wounds including 325 patients, most
of whom were at either high or unclear risk of bias. The
technical specifications for PRP preparation were varied
as were the clinical applications of prepared material. How-
ever, there are other promising indications for PRP appli-
cations, and these include:
i. accelerating the healing of bone fracture sites and/or
bone grafts; particularly for maxillofacial indica-
tions13,15,16
ii. treating tendinopathies especially in Achilles ten-
don problems and rotator cuff tissue repair17,18
iii. application in aesthetic surgery as a filler and for
skin rejuvenation in order to enhance the take of
adipose tissue grafts19
iv. treating chronic non-healing wounds such as those
of diabetic patients who are at risk of impaired
wound healing,8
v. treating acute and chronic wounds, severe burns,
and associated skin graft donor sites which are nec-
essary in patient management
vi. taken all together, the most promising areas for us-
ing PRP use seem to be for tendinopathies.7,17,18
Large prospective and randomized studies will be nec-
essary to investigate the efficacy of standardized prepara-
tions of PRP in wound healing.
It is proposed that the first step towards this stan-
dardization should be the production of a more cost ef-
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fective and therefore more accessible PRP preparation
method which would make PRP more readily available to
a higher number of patients and treatment centres and fa-
cilitate the development and design of adequate powered
clinical studies.
Overall, the PRP preparation technique we describe
in this report can be implemented in most clinical settings
and can be properly implemented by trained medical staffs,
with no additional specialized training, as they are already
aware of all risks related to harvesting, transportation, pro-
cessing, and injection or application of the PRP to the pa-
tient.
Conclusions
We report a cost-effective method of PRP preparation
aiming to obtain maximal protection for the cellular ele-
ments. PRP can be used for treatment and stimulation of
healing of wounds of all types including burns and also
split-thickness skin graft donor sites used frequently for
burn management. The procedure can be easily adapted to
most clinical settings with minimal infrastructure so that
many patients can benefit from this cellular therapy and
so that robust, clinical studies can be accomplished with-
out the high economic outlay starting material costs. 
RÉSUMÉ. Le plasma riche en plaquettes (PRP) est un volume de la fraction plasmatique du sang autologue ayant des concentra-
tions au-dessus des valeurs de base des plaquettes sang total en raison de l’élaboration et de la concentration. Le PRP est utilisé
dans différents domaines de la chirurgie pour améliorer la guérison des tissus mous et des os en délivrant des concentrations su-
praphysiologiques de plaquettes autologues au niveau du site de lésion tissulaire. Ces préparations peuvent fournir une bonne sour-
ce cellulaire de divers facteurs de croissance et, de cytokines et moduler la réponse tissulaire à une lésion. Des matériaux com-
muns cliniquement disponibles pour des préparations hématiques en association avec un protocole de centrifugation en deux étapes
à 280g chacun, afin d’assurer l’intégrité des composants cellulaires, ont fourni des préparations de plaquettes qui ont été concen-
trées 2-3 fois par rapport aux valeurs de sang total. Les coûts se sont avérés inférieurs à ceux des autres méthodes qui nécessitent
un équipement spécifique et des jetables ayant un coût élevé, tandis que la sécurité et la traçabilité peuvent être augmentées. Le
PRP peut être utilisé pour le traitement de tous les types de lésions, y compris les brûlures comme aussi pour le traitement des
sites donateurs de greffes cutanées d’épaisseur variable, qui sont fréquemment utilisées dans la gestion des brûlures. La procédure
peut être standardisée et facilement adaptée dans les milieux cliniques avec une infrastructure minimale, permettant ainsi à un grand
nombre de patients de bénéficier de cette forme de thérapie cellulaire.
Mots-clés: plaquettes, PRP, thérapie cellulaire, réparation des tissus, économie sanitaire
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